Fabian-Alexander Schleich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fabian-Alexander Schleich has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Agnes A. Walsh
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, USA
1 shared publication- Andrew B. Ward
Scripps Research Institute
1 shared publication - Darrell J. Irvine
The Scripps Research Institute
1 shared publication Diane Carnathan
Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, USA
1 shared publication- Gabriel Ozorowski
Scripps Research Institute
1 shared publication - Guido Silvestri
Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 29 April 2026
- Published by Springer Nature in Nature
- Vol. 654 (8119) , 777-785
Vaccination generates broadly cross-neutralizing antibodies to the HIV Env apex
As a chronically replicating virus, HIV has evolved extreme sequence variability and effective shielding of functionally constrained spike protein determinants by host-derived glycans 1 . Broadly neutralizing antibodies, although rare, can be isolated from people living with HIV, revealing conserved envelope glycoprotein (Env) sites as key targets for vaccine development 2–4 . One such target is the apex of the Env spike. Here we identify a vaccination strategy using heterologous HIV Env trimers covalently coupled to liposomes for multivalent display that resulted in the elicitation of cross-neutralizing HIV serum antibody responses in all trimer-liposome-immunized non-human primates. Critically, we isolated monoclonal antibodies from multiple macaques that cross-neutralize divergent HIV clinical isolates. High-resolution cryogenic electron microscopy structural analyses of monoclonal antibodies from four different macaques demonstrate that they target the Env trimer apex in a manner highly similar to that of the human-infection-elicited, apex-directed broadly neutralizing antibody PG9, representing a substantial advance in HIV vaccine development.
- 29 April 2026
- Published by Springer Nature in Nature
- Vol. 654 (8119) , 777-785
Top Cited PapersOpen AccessVaccination generates broadly cross-neutralizing antibodies to the HIV Env apex
As a chronically replicating virus, HIV has evolved extreme sequence variability and effective shielding of functionally constrained spike protein determinants by host-derived glycans 1 . Broadly neutralizing antibodies, although rare, can be isolated from people living with HIV, revealing conserved envelope glycoprotein (Env) sites as key targets for vaccine development 2–4 . One such target is the apex of the Env spike. Here we identify a vaccination strategy using heterologous HIV Env trimers covalently coupled to liposomes for multivalent display that resulted in the elicitation of cross-neutralizing HIV serum antibody responses in all trimer-liposome-immunized non-human primates. Critically, we isolated monoclonal antibodies from multiple macaques that cross-neutralize divergent HIV clinical isolates. High-resolution cryogenic electron microscopy structural analyses of monoclonal antibodies from four different macaques demonstrate that they target the Env trimer apex in a manner highly similar to that of the human-infection-elicited, apex-directed broadly neutralizing antibody PG9, representing a substantial advance in HIV vaccine development.